Immutep takes immunotherapy a step further with 'impressive' survival data from Keytruda combo

Immutep believes its LAG-3 candidate eftilagimod alpha may have a path to approval in first-line head and neck cancer after reporting what one analyst deems “impressive” overall survival data.